These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 34984595)
1. Microrheological disorders in patients with polycythemia vera suffered acute ischemic stroke. Tanashyan M; Shabalina A; Roitman E Mol Cell Biochem; 2022 Apr; 477(4):989-994. PubMed ID: 34984595 [TBL] [Abstract][Full Text] [Related]
2. Red Blood Cell Morphodynamics in Patients with Polycythemia Vera and Stroke. Kuznetsova PI; Raskurazhev AA; Shabalina AA; Melikhyan AL; Subortseva IN; Tanashyan MM Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216363 [TBL] [Abstract][Full Text] [Related]
3. Ischemic stroke as a presenting manifestation of polycythemia vera: a narrative review. Burattini M; Falsetti L; Potente E; Rinaldi C; Bartolini M; Buratti L; Silvestrini M; Viticchi G Rev Neurosci; 2022 Apr; 33(3):303-311. PubMed ID: 34508650 [TBL] [Abstract][Full Text] [Related]
4. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Bellucci S; Michiels JJ Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614 [TBL] [Abstract][Full Text] [Related]
5. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568 [TBL] [Abstract][Full Text] [Related]
6. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia]. Iványi JL; Marton E; Plander M Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365 [TBL] [Abstract][Full Text] [Related]
7. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274 [TBL] [Abstract][Full Text] [Related]
8. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Finazzi G; Rambaldi A; Guerini V; Carobbo A; Barbui T Haematologica; 2007 Jan; 92(1):135-6. PubMed ID: 17229651 [TBL] [Abstract][Full Text] [Related]
9. Thrombosis among 1537 patients with JAK2 Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332 [TBL] [Abstract][Full Text] [Related]
10. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893 [TBL] [Abstract][Full Text] [Related]
11. Erythrocyte deformability evaluated by laser diffractometry in polycythemia vera. Lo Presti R; Caracciolo C; Montana M; Barone R; Catania A; Caimi G Clin Hemorheol Microcirc; 2012; 50(3):189-92. PubMed ID: 22240347 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center. Davila-Gonzalez D; Barrios-Ruiz A; Fountain E; Cheng L; Masarova L; Verstovsek S; Rojas-Hernandez CM Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):224-229. PubMed ID: 33349602 [TBL] [Abstract][Full Text] [Related]
13. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Vannucchi AM; Antonioli E; Guglielmelli P; Rambaldi A; Barosi G; Marchioli R; Marfisi RM; Finazzi G; Guerini V; Fabris F; Randi ML; De Stefano V; Caberlon S; Tafuri A; Ruggeri M; Specchia G; Liso V; Rossi E; Pogliani E; Gugliotta L; Bosi A; Barbui T Blood; 2007 Aug; 110(3):840-6. PubMed ID: 17379742 [TBL] [Abstract][Full Text] [Related]
14. Ischemic stroke as an initial performance of polycythemia vera in young adults: A case report and literature review. Hui S; Zhao J; Huo T; Dong L; Xie Y; Wang X; Zhang M Medicine (Baltimore); 2024 Feb; 103(7):e36953. PubMed ID: 38363912 [TBL] [Abstract][Full Text] [Related]
15. [Blood rheologic disorders in patients with polycythemia vera and their correction by therapeutic erythrocytapheresis]. Likhovetskaia ZM; Prigozhina TA; Gorbunova NA; Kalinin NN; Petrov MM Gematol Transfuziol; 1989 Nov; 34(11):33-6. PubMed ID: 2612862 [TBL] [Abstract][Full Text] [Related]
18. Abnormal adhesion of red blood cells in polycythemia vera: a prothrombotic effect? El Nemer W; De Grandis M; Brusson M Thromb Res; 2014 May; 133 Suppl 2():S107-11. PubMed ID: 24862129 [TBL] [Abstract][Full Text] [Related]
19. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM. Wautier MP; El Nemer W; Gane P; Rain JD; Cartron JP; Colin Y; Le Van Kim C; Wautier JL Blood; 2007 Aug; 110(3):894-901. PubMed ID: 17412890 [TBL] [Abstract][Full Text] [Related]
20. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera. Pósfai É; Marton I; Borbényi Z; Nemes A Anatol J Cardiol; 2016 Jun; 16(6):397-402. PubMed ID: 27182615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]